Recent

% | $
Quotes you view appear here for quick access.

OncoSec Medical Incorporated Message Board

waitforit52 65 posts  |  Last Activity: Apr 24, 2015 6:51 PM Member since: Nov 2, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Furb? Guti? Wait?

    by searchingoil Apr 24, 2015 3:03 PM
    waitforit52 waitforit52 Apr 24, 2015 6:51 PM Flag

    Mensa? Is that you?

  • Reply to

    Serious Question

    by jbem777 Apr 23, 2015 2:25 PM
    waitforit52 waitforit52 Apr 23, 2015 2:38 PM Flag

    Jbem--I'm amazed your wife has stayed with you this long. Don't bother responding--you're on ignore. Sorry for your own bad judgement & childish, emotional outbursts where ever you go, but frankly I'm glad to hear you're leaving--you are leaving...please say you're leaving!?! And yes, you're on ignore at IHUB too!

    P.S. See my post on "LPSD" --it explains you're symptoms!

    Sentiment: Strong Buy

  • Reply to

    Stocks are not for the weak.

    by kar26dav Apr 22, 2015 3:38 PM
    waitforit52 waitforit52 Apr 23, 2015 10:03 AM Flag

    Spoken like a true GTHP pumper--:(

    Sentiment: Strong Buy

  • waitforit52 waitforit52 Apr 22, 2015 6:41 PM Flag

    Alright once upon a time, I'm putting my last pennies in at these prices . I'm sorry that it's shaking out so many weak Hands, But you can't pass up these prices with a company like this that has the potential of getting the corner on this market of nonresponders – especially at these prices!

  • waitforit52 waitforit52 Apr 22, 2015 6:38 PM Flag

    Along with what Brian said, look out for a surprise from IL 15 and its application with the electroporation platform.

    Sentiment: Strong Buy

  • waitforit52 waitforit52 Apr 22, 2015 6:37 PM Flag

    Yeah Dirk, I know this is been set a lot over the last three years. But the next 6 to 8 months will provide plenty of information to decide whether this company is going to be able to accomplish its business plan of increasing tumor infiltrating lymphocytes along with the synergy with other drugs . I think the beauty of this along with the power of it is going to come with just a little bit of positive data demonstrating that ability to succeed in this niche that has such huge potential.

    I also think it's important to remember that the success is being reported in these other combination trials often has to do with just extending life and extra six months and it doesn't even address the three quarters of the cancer population that their combination of drugs can't even reach.

    Sentiment: Strong Buy

  • "LPSD" -- Low Price Share Disorder!
    Symptoms:

    Heart palpitations,

    sweaty palms,

    chronic complaining of Executive Officers "Off with his head!"

    Blaming the company for one's own entry and exit decisions.

    Demands for PPS to be manipulated by Corporation (like twitter) to counter the MM's manipulation,

    Loss of awareness of Science paradigm shifts and need adjustments required by related companies,

    Investment strategy shifts to "buy High and sell Low" regardless of solid fundamentals and science,

    Bashers start to sound like they have your best interest at heart,

    Percistant need to have one's hand be held

    Loss of both courage and patience

    If you find yourself suffering from any or all of these, I suggest you meditate on some truisms regarding OncoSec:

    This biotech company is making a powerful transition away from chemotherapy to the NEW immunotherapy paradigm. There's no pump and dump at work here. And there is no need for reassurance and confidence, Because this company isn't about price per-share manipulation. Having your facts straight about the science, about the scientists, about systemic affect, increasing Tumor Infiltrating Lymphocytes- non-responders to responders, minimal to no side effects, low-cost, outpatient, compatible with multiple medications across multiple indications with multiple companies. My suggestion is to Hold position and buy on these wonderful MM manipulated dips.

    Now if you'll excuse me, I'm going to go Doublecheck my buy order for 80,000 shares at $.25 price point.

    Sentiment: Strong Buy

  • Reply to

    How about the insiders buy some freaking shares!?

    by mrmeshuga Apr 21, 2015 9:58 PM
    waitforit52 waitforit52 Apr 22, 2015 11:55 AM Flag

    hey capt. you must have gotten mine cuz I never received one.

    Sentiment: Strong Buy

  • Reply to

    Furbush

    by mlbull34 Apr 21, 2015 3:21 PM
    waitforit52 waitforit52 Apr 21, 2015 4:10 PM Flag

    This quote is from a recent Dr. Algazi, who is an investigator for Oncosec, and who "reports research funding from GlaxoSmithKline and Merck.

    "According to the author, Oncosec will be using pembrolizumab to increase the power of IL-12 without the worries of an increase in toxicity, while studying the likelihood that the combination will have an effect on non-responders. This explains why Merck at this point is not fully committed, since the testing will only benefit Oncosec, except if it has a positive benefit on the non-responders."

    This is OncoSec utilizing Merck's "best in class" drug, not Merck using Oncosec's electroporation. It is not the device that matters here (key component, yes), but that IL12 + electroporator patented platform yields local powerful effects and systemic efftect on untreated tumors----as well as, increased TIL's from non-responders to responders.

    Merck in not in our driver's seat, it is Oncosec using the fuel of Ketruda to reach their destination of licensing to multiple companies, multiple drugs, reaching multiple indications.

  • Reply to

    I give up .....Im out ......

    by pacwoman44 Apr 21, 2015 12:57 PM
    waitforit52 waitforit52 Apr 21, 2015 1:17 PM Flag

    That's right – – buy high and sell low-- I pity you daytraders. I would suggest a better move… Put in a buy order for however many shares you can afford at a $.25 price point – and then get a grip and hold on till December – You'll thank me later!

    Sentiment: Strong Buy

  • Reply to

    The CANCER revolution- FORBES article

    by flightplan747 Apr 20, 2015 10:38 AM
    waitforit52 waitforit52 Apr 20, 2015 2:18 PM Flag

    Thought I'd give you a hand Flight...
    PHILADELPHIA (TheStreet) -- Treatment with the cancer immunotherapy known as chimeric antigen receptor T cells, or CAR-T, was found to be relatively safe and feasible in an early-stage study involving a small number of patients with advanced solid tumors, researchers said Sunday.
    The data are preliminary but significant as an indication that CAR-T therapies might have a role as a treatment in the much larger solid tumor cancer market. To date, all of the excitement surrounding CAR-T has come from very high remission rates in patients with advanced blood cancers, a smaller commercial market.
    The phase I study was conducted using a CAR-T therapy from Novartis (NVS - Get Report) and the University of Pennsylvania. T cells were taken out of patients and modified with receptors to identify a protein known as mesothelin expressed on the surface of certain tumors. The modified T cells, now able to detect and kill mesothelin-containing tumors, were then grown and reinfused back into the patients.
    The new immunotherapy, known as CART-meso (short for mesothelin), was administered to five patients with advanced cancers no longer responding to multiple lines of prior therapy. Two patients had ovarian cancer, two had epithelial mesothelioma (a type of lung cancer) and one patient had pancreatic cancer.
    No major adverse events associated with the infusion of CART-meso were reported in the five patients, although other serious side effects, including sepsis, shortness of breath and elevated white-blood-cell counts were reported during follow-up. In addition, the modified T cells were detectable in patients' blood for up to 28 days following infusion, and there was some evidence that the T cells migrated to the tumors, said principal investigator Dr. Janos Tanyi of the University of Pennsylvania.
    "The interim results to date indicate that the therapy is safe in the patients treated so far," Tanyi said, in a statement. Results from the phase I study were disclosed Sunday at the American Association for Cancer Research (AACR) annual meeting.
    CART-meso appears well-tolerated so far, but does it work? Anti-tumor efficacy in the study was "suggested" by the clearing of malignant cells in the fluid surrounding the lungs of a single patient, researchers said. There was also imaging and clinical evidence of a tumor stabilizing or shrinking in another patient.
    Mesothelin is also found in normal tissue, raising concern that the modified T cells would not only target and kill tumor cells, but also damage healthy tissue and organs. Researcher found some evidence that the CART-meso could be detected in the fluid around the heart of patients, but there were no related toxicities reported.
    "We are still evaluating the CART-meso program, so really have no further details to share at this time," said Novartis spokeswoman Dana Cooper, in response to a question about the company's plans to advance CART-meso or any other CAR-T therapies directed at solid tumors. 

    Juno Therapeutics (JUNO) and Kite Pharma (KITE) both have similar solid tumor CAR-T projects under way, some in more advanced stages.

    Sentiment: Strong Buy

  • Since 1993, BioCentury Publications, Inc. has been internationally recognized as the leading provider of value-added information, analysis and data for biotechnology and pharmaceutical companies, investors, academia and government on the strategic issues essential to the formation, development and sustainability of life science ventures. Recently a senior writer published an article titled “New players in PD-1 combination therapy” Product R&D: Company Check Points, in which he mentioned the importance of the research being done by Oncosec utilizing IL-12 for helping anti-PD1 non-responders, which constitute the majority of cancer patients.
    Part of the article states, “the spate of biotechs announcing new targets, combinations or milestones in the PD-1 space in the last two months suggests pharmas may not have to wait long to add second-generation therapies to their pipelines of checkpoint inhibitors. While AnaptysBio Inc. and cCAM have preclinical targets that could complement PD-1 inhibition, OncoSec Medical Inc. is about to enter the clinic with a combination that uses PD-1 suppression to potentiate the immune activation of IL-12.
    The push for new compounds is driven by the fact that many patients don't respond to PD-1 therapies because their tumors have either low or no expression of the receptor's ligand, PD-L1. By acting through complementary pathways, upregulating the expression of PD-L1 or increasing the ability of antigen-presenting cells to trigger immune pathways, the next generation of compounds is designed to potentiate the tumor-killing effect of PD-1 inhibitors.”
    According to the author, Oncosec will be using pembrolizumab to increase the power of IL-12 without the worries of an increase in toxicity, while studying the likelihood that the combination will have an effect on non-responders. This explains why Merck at this point is not fully committed, since the testing will only benefit Oncosec, except if it has a positive benefit on the non-responders.

    Sentiment: Strong Buy

  • Reply to

    ATHX Went Up In Flames!!!

    by golf.paul123 Apr 17, 2015 12:16 PM
    waitforit52 waitforit52 Apr 17, 2015 4:45 PM Flag

    Golf, you've started weekend with a good chuckle--have a great weekend my fellow long.
    P.S. Remember if oncs drops next week--look for .25 as a good refill price point to pick up more shares -- I agree with Ken.investor-- "imminent" (def.: about to happen!)

    Sentiment: Strong Buy

  • waitforit52 waitforit52 Apr 17, 2015 9:13 AM Flag

    I say take her down, we can will sell me more shares at a great price– – Because will be moving on up by the beginning of third-quarter.

    Sentiment: Strong Buy

  • waitforit52 waitforit52 Apr 16, 2015 10:58 AM Flag

    Amen Flight! Amen....

    Sentiment: Strong Buy

  • waitforit52 waitforit52 Apr 16, 2015 6:46 AM Flag

    Can't wait 'till we get some fresh data on anything pertaining to TIL's

    Sentiment: Strong Buy

  • Reply to

    For Tasso and his desire for a buyout?

    by waitforit52 Apr 15, 2015 11:46 AM
    waitforit52 waitforit52 Apr 15, 2015 11:56 AM Flag

    I know Bro..., it's more for conversation sake.

    Sentiment: Strong Buy

  • Hey Tasso, why the need for a buyout? Other than it is what makes short-term investors happy. Personally, and I've stated this before, that licensing to multiple companies, for multiple drugs, over multiple indications is where the long term money is to be made. I believe that is why OncoSec positioned themselves to evaluate immunopulse, in combination with the PD-1 drug in the trial.

    Looking for companies to “partner” with (not be “Bought out” by), I believe, has been according to a business plan. I say this because They are looking to demonstrate the increase of TILs using the best PD-1, of which, “Keytruda” happens to be the best at present.

    IF they demonstrate top-line data with a top-of-the-line PD-1 like Keytruda...imagine what other companies will be thinking, “how can ImmunoPulse enhance our PD-1, PD-L1?” Not to mention companies like HEAT biologics, seeing the potential with their alternative immunotherapy drugs. I'm going on record (but more than willing to be wrong) to say OncoSec is positioning itself (everyone's opinion of Punit, notwithstanding) to be an industry leader in solid tumor oncology.

    The upside potential is far greater than many short termer's here have the vision for while they play for pennies --- Hense the proliferation of the bashers on the when's and won'ts of the upswings and downswings of PPS.

    ImmunoPulse alone (forget about IL-15 and the rest of their R&D immunotherapy puzzle pieces), is so well positioned in this scientific niche of increasing TIL's and enhancing responses, both in the quality and quantity of patients who would otherwise have their cancer kicked down the road to surgery, radiation, lower efficacy, lower Over All Response chances, higher costs, etc., etc., is a SLEEPER in this budding Immunotherapy Advancement.

    OncoSec holds (at present) the scientific lead in potentially enhancing almost ALL OTHER CANCER DRUGS to function with greater safety and efficacy to the unreached non-responder masses. If you not clear on this, just look up clinicaltrials.gov and type in Tumor Infiltrating Lymphocyte, and notice there is not a single trial able to produce a measurable increase of TIL's like OncoSec's pilot study in Triple Negative Breast Cancer and Head and Neck Cancer.

    And take note, the non-responder percentage represents ONLY the drugs in the Anti-PD1. In Some cases a PD-L1 drug yield a better clinical outcome, but they will desire enhancement of their patient populations as well.

    THE UNMET MEDICAL NEED
    Anti-PD1 non-responders constitute the majority of patients, even in “immune therapy” tractable tumors
    ***Non-Response
    Melanoma ~ 60 - 80%

    Triple Negative Breast (TNBC)~ 70% - 82%

    Renal Cell Carcinoma of the kidney (RCC)~ 71%

    Lung Carcinoma (NSCLC)~ 79 – 83%

    Head and Neck (H&N)~ 80%

    Bladder~ 84%

    This might be

    With a solid foundation of results showing that immunopulse in creases TIL's as evidenced by Dr. Alain Algazi's article that I posted yeasterday, the problem won't be with TIL production, but rather, synergy in the combination themselves. By synergy I mean by definition: “the interaction of elements that when combined produce a total effect that is greater than the sum of the individual elements.”

    This is what OncoSec is working toward—a synergistic platform to be licensed to empower multiple cancer indications and the drugs that serve them.

    The Google board has put a present valuation of $1 billion as of today. That's a $4 PPS.

    I'd like to offer my evaluation for where OncoSec is heading. This is from a post I put together back in late Noverber and noting has changed except other companies wishing to collaborated with us.

    I'll use six cancer indications that I lifted from Oncosec presentation slides. It will include the number of cases per year in that indication the percentage of non-responders, the number that that yields, The total number of available non-responders.

    *These are new cases every year...
    Melanoma = 76,000, 70% non-responders comes to 53,200
    Renal cell (Kidney) carcinoma = 61,560, 70% non-responders comes to 43,092
    Lung carcinoma = 220,000, 80% non-responders comes to 176,000
    Head and neck cancer = 55,000, 80% non-responders comes to 44,000
    Bladder cancer = 75,000, 75% non-responders comes to 76,250
    Breast-cancer = 222,000, 75% non-responders comes to 166,500

    Total number of non-responders = 497,000
    Using lasers minimum cost per person per treatment of $20,000, multiplied by the total number of non-responders comes to an annual revenue of: $10,780,840,00-- divided by total number of shares of 245 million, comes to a PPS valuation of $40.57.

    It's a very rough example on only six indications which are a ways off, but I think it's important to at least appreciate the potential of this company when considering only six indications and only non-responders. Oncosec is developing its own drugs and multiple indications and multiple combinations. The other consideration is to realize Biotech is often priced 3 to 4 times it's valuation and PPS.

    It's just a selling point and a talking point to consider when people are hoping for a buyout for three dollars compared to what the market will actually value this company should the non-responder combination approach really comes through and be factored in to the company's worth.

    Sentiment: Strong Buy

  • waitforit52 waitforit52 Apr 15, 2015 9:15 AM Flag

    Doesn't matter to me cuz i'm not a day trader--they'll start it when they're inline with FDA combination protocols.

    Sentiment: Strong Buy

  • Plasmid IL-12 electroporation shows promise in melanoma
    April 11, 2015

    NEW YORK — Intratumoral plasmid interleukin-12 electroporation was associated with local necrosis and increased tumor infiltrating lymphocytes and can lead to systemic tumor regression in melanoma, according to study results presented at the HemOnc Today Melanoma and Cutaneous Malignancies meeting.

    See Also
    IL-12 plasmid electroporation appears effective in metastatic ...
    Electro-Gene Therapy with IL-12 plasmid in metastic ...
    Types of genetic testing for melanoma discussed at AAD
    These benefits warrant the study of plasmid interleukin (IL)-12 electroporation in combination with anti-programmed cell death-1 (PD-1) monoclonal antibodies, Alain Algazi, MD, of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, said during his presentation.
    “IL-12 is a key cytokine, and might be really important in terms of stimulating an anti-tumor immune response, but if you give it systemically, it is toxic,” Algazi said. “This is a way that you can give a concentrated amount of IL-12 into the tumor, with a focal intervention that is more tolerable.”
    Algazi and colleagues developed a platform for treatment where researchers inject plasma DNA into the tumor and then give an electric current to the site in order to make holes in the tumor cells. The tumor can then take up the plasma and start expressing IL-12.
    “This is a platform that can be used for any variety of things you’d want to express, but IL-12 is a particularly appropriate focal intervention that might cause the tumor inflammation we’re looking for to get an anti-tumor immune response,” Algazi said.
    Algazi and colleagues conducted a phase 1 study evaluating plasmid IL-12 electroporation in 24 patients. Patients received intratumoral plasmid IL-12 electroporation on days 1, 5 and 8. Using biopsy samples from two patients, researchers noted dense tumor infiltrating lymphocyte (TIL) populations by 22 days, and by 18 months there were no residual melanoma cells, Algazi said.
    Overall, two patients achieved a complete response — one which lasted longer than 16 months and the other longer than 20 months — and six patients achieved stable disease that ranged from 4 months to 6 months.
    Based on these data, researchers conducted a phase 2 trial in 30 patients (median age 67 years, 53.3% male). Patients had unresectable stage IIIB/C melanoma or stage IV melanoma, and 55.2% had received prior immunotherapy.
    Overall, treatment was well tolerated, Algazi said. The most common adverse event was pain (87%), the median duration of which was 1 minute. The median pain score was 3 immediately after treatment, but 5 minutes later the pain score decreased to 0.
    Four patients achieved a complete response, five achieved a partial response and five patients achieved stable disease. The overall response rate was 31% and the disease control rate was 48%.
    The median duration of response was 3.2 months (range, 2.1-16.6) and the median duration of disease control was 5.9 months (range, 2.7-16.6).
    Intratumoral plasmid IL-12 electroporation promoted local and systemic anti-tumor immunity, Algazi said. Of 26 evaluable patients, 50% had distant lesion regression.
    Median PFS was 3.1 months.
    “You can get objective responses with single-agent plasmid IL-12 electroporation, and it appears to be well tolerated except for the pain associated with treatment,” Algazi said. “Preliminary data suggest we’re getting inflammation in the tumor, which is part one of the two-part immune response. We need inflammation in the tumor and we need immune cell infiltration and cytokine elaboration, and that might be what we really need to synergize with the PD-1/PD-L1 antibody checkpoint inhibitor.”
    Researchers plan to open a study evaluating the combination of pembrolizumab (Keytruda, Merck) and intratumoral plasmid IL-12 electroporation this year, Algazi said. — by Alexandra Todak
    For more information:
    Algazi A. Plasmid Il-12 electroporation in melanoma. Presented at: HemOnc Today Melanoma and Cutaneous Malignancies; April 10-11, 2015; New York.
    Disclosure: Algazi reports research funding from GlaxoSmithKline and Merck.

    Sentiment: Strong Buy

ONCS
0.268-0.009(-3.42%)Apr 24 3:56 PMEDT